GlassScriptPhysician profile
Moira S Post
NPI 1396897187
$688.38
in general payments reported to CMS, 2019-2025
13 companies · $415 in 2025
The $415 reported for 2025 was more than what 96% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
See the full distribution for Nurse Anesthetist, Certified Registered
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.00 · 2024: $231 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $184.14 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $108.75 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $84.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $55.45 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $53.92 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.84 | 2024-2025 | Trulance, Relistor, Plenvu |
| Medtronic, INC. | $42.00 | 2021 | |
| Genzyme Corporation | $25.09 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.90 | 2025 | Suflave |
| Lilly USA, LLC | $18.53 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $18.21 | 2024 | Dificid |
| Janssen Biotech, INC. | $16.95 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $14.07 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moira Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.